These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27188479)

  • 1. Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.
    Hoogwerf BJ; Lincoff AM; Rodriguez A; Chen L; Qu Y
    Cardiovasc Diabetol; 2016 May; 15():78. PubMed ID: 27188479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
    Ginsberg H; Cariou B; Orchard T; Chen L; Luo J; Bastyr EJ; Bue-Valleskey J; Chang AM; Ivanyi T; Jacober SJ; Hoogwerf BJ
    Diabetes Obes Metab; 2016 Nov; 18(11):1089-1092. PubMed ID: 27486125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
    Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
    Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial.
    Grunberger G; Chen L; Rodriguez A; Tinahones FJ; Jacober SJ; Bue-Valleskey J;
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():34-42. PubMed ID: 27723225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.
    Jacober SJ; Prince MJ; Beals JM; Hartman ML; Qu Y; Linnebjerg H; Garhyan P; Haupt A
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():3-16. PubMed ID: 27723228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
    Rosenstock J; Marx N; Neubacher D; Seck T; Patel S; Woerle HJ; Johansen OE
    Cardiovasc Diabetol; 2015 May; 14():57. PubMed ID: 25990013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
    Cusi K; Sanyal AJ; Zhang S; Hoogwerf BJ; Chang AM; Jacober SJ; Bue-Valleskey JM; Higdon AN; Bastyr EJ; Haupt A; Hartman ML
    Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():50-58. PubMed ID: 27723227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
    Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
    Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
    Johansen OE; Neubacher D; von Eynatten M; Patel S; Woerle HJ
    Cardiovasc Diabetol; 2012 Jan; 11():3. PubMed ID: 22234149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
    Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
    Sonesson C; Johansson PA; Johnsson E; Gause-Nilsson I
    Cardiovasc Diabetol; 2016 Feb; 15():37. PubMed ID: 26895767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.
    Buse JB; Rodbard HW; Trescoli Serrano C; Luo J; Ivanyi T; Bue-Valleskey J; Hartman ML; Carey MA; Chang AM;
    Diabetes Care; 2016 Jan; 39(1):92-100. PubMed ID: 26577417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
    Ratner R; Han J; Nicewarner D; Yushmanova I; Hoogwerf BJ; Shen L
    Cardiovasc Diabetol; 2011 Mar; 10():22. PubMed ID: 21410975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
    Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
    Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
    Rosenstock J; Marre M; Qu Y; Zhang S; Bastyr EJ; Prince MJ; Chang AM
    Diabetes Obes Metab; 2016 Nov; 18(11):1093-1097. PubMed ID: 27484021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin.
    McMurray JJV; Solomon SD; Lock JP; Massaro JM; Zhu F; Zhou W; Skali H; Lewis EF; Freeman MW; Halvorsen YC
    Diabetes Obes Metab; 2024 Mar; 26(3):971-979. PubMed ID: 38151752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
    Porksen N; Linnebjerg H; Garhyan P; Lam EC; Knadler MP; Jacober SJ; Hoevelmann U; Plum-Moerschel L; Watkins E; Gastaldelli A; Heise T
    Diabetes Obes Metab; 2017 Apr; 19(4):482-488. PubMed ID: 27888561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
    Green JB; Everett BM; Ghosh A; Younes N; Krause-Steinrauf H; Barzilay J; Desouza C; Inzucchi SE; Pokharel Y; Schade D; Scrymgeour A; Tan MH; Utzschneider KM; Mudaliar S;
    Circulation; 2024 Mar; 149(13):993-1003. PubMed ID: 38344820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.